Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 7/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.49 |
| ▸ | TUBB | P07437 | 6/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723242 | 0.83 | EGFR (0.50) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL724651 | 0.80 | TUBB4A (0.49) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL725347 | 0.79 | TUBB4A (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL25478528 | 0.78 | TUBB1 (0.43) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL725053 | 0.78 | PDGFRB (0.50) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL723931 | 0.78 | TUBB1 (0.57) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4418355 | 0.78 | TUBB4A (0.57) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL726093 | 0.78 | EGFR (0.51) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23734271 | 0.77 | TUBB1 (0.48) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL24222511 | 0.77 | TUBB1 (0.48) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2021203100-A9 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB1 132/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB1 132/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | TUBB1 2/4885TUBB4A 7/4885TUBB 3/4885 |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | TUBB1 2/4885TUBB4A 7/4885TUBB 3/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB1 132/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB1 132/4885TUBB4A 296/4885TUBB 213/4885 |
| US-11648236-B2 | Methods of treating coronavirus | TUBB3, TUBB1, TUBB | TUBB1 2/4885TUBB4A 7/4885TUBB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.